Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML

NCT01664897 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01664897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01664897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
May 16, 2013
Completion date
October 25, 2018
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia arising from previous myelodysplastic syndrome, adult acute myeloid leukemia with inv(16)(p13.1q22); cbfb-myh11, adult acute myeloid leukemia with t(16;16)(p13.1;q22); cbfb-myh11, adult acute myeloid leukemia with t(8;21); (q22; q22.1); runx1-runx1t1, adult acute myeloid leukemia with t(9;11)(p22.3;q23.3); mllt3-kmt2a, adult acute promyelocytic leukemia with pml-rara, alkylating agent-related acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia